Hesperetin, a naturally occurring flavonoid with notable anti-inflammatory and antioxidant properties, has shown promising effects in addressing liver fibrosis, a condition characterized by excessive scarring due to chronic liver injury. In a mouse model of carbon tetrachloride-induced liver fibrosis, hesperetin demonstrated significant antifibrotic potential.
Hesperetin, a naturally occurring flavonoid with notable anti-inflammatory and antioxidant properties, has shown promising effects in addressing liver fibrosis, a condition characterized by excessive scarring due to chronic liver injury. In a mouse model of carbon tetrachloride-induced liver fibrosis, hesperetin demonstrated significant antifibrotic potential. It reduced liver injury and fibrosis, improved liver tissue structure, and suppressed autophagy-related markers in hepatic stellate cells, which are key drivers of fibrosis. By inhibiting the activation of these cells, hesperetin effectively limited the progression of fibrosis and decreased inflammatory cell infiltration within the liver.
Additionally, hesperetin influenced gut microbiota composition, an important factor in liver health. Using 16S rDNA sequencing, researchers observed that hesperetin increased the proportion of Firmicutes and boosted beneficial populations of lactic acid bacteria. These changes in gut microbial balance contributed to reduced liver inflammation and fibrosis, highlighting the gut-liver axis's role in disease modulation.
The study concluded that hesperetin alleviates liver fibrosis through a multifaceted mechanism involving the suppression of hepatic stellate cell autophagy, reduction of inflammation, and restoration of healthy gut microbiota. These findings suggest hesperetin as a potential therapeutic candidate for managing liver fibrosis and improving overall liver health.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.